Prediction of Residual Disease by Circulating DNA Detection After Potentiated Radiotherapy for Locally Advanced Head and Neck Cancer

Sixty percent of newly diagnosed head and neck squamous cell carcinomas (HNSCCs) are at a locally advanced (LA) stage. Depending on tumor site, stage, and resectability, locoregional failure rates can range from 35% to 65%. The persistence of residual disease at the end of treatment is a major prognostic element but is not always reliably assessed by current imaging techniques. Up to 40-50% of patients have residual adenomegaly and only 30% have viable disease when further adenectomy is performed. Sensitive and reproducible detection of residual disease after treatment is a major challenge in

Trial Details

NCT ID
NCT05710679
Phase
NA
Sponsor
Centre Jean Perrin
Status
RECRUITING
Cancer Type
HPV Positive Head and Neck Cancer
Interventions
  • Blood sample
Locations (sample)
  • Clermont-Ferrand, Puy-de-Dôme, France|45.77969,3.08682
  • Lyon, France|45.74906,4.84789
  • Saint-Etienne, France|45.43389,4.39

Key Eligibility Criteria

  • Age ≥ 18 years and ≤ 80 years
  • Histologically confirmed, never treated squamous cell carcinoma with lymph node involvement
  • squamous cell carcinoma p16+or p16-, stage III (N1), IVa or IVb (UICC classification 8th edition), N1 minimum, and oropharyngeal sqamous cell carci…
  • Oral cavity, oropharynx, hypopharynx or larynx, cervical adenopathies without primary

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HPV Positive Head and Neck Cancer Trials on Trialify →